Chronic intervillositis of unknown etiology
KRAH-nik in-ter-VIL-oh-SY-tis of un-NOHN ee-tee-OL-oh-jee
Also known as: CIUE, Chronic histiocytic intervillositis
At a Glance
What is Chronic intervillositis of unknown etiology?
Chronic intervillositis of unknown etiology is a rare condition affecting the placenta during pregnancy. It primarily impacts the reproductive system, specifically the placenta, which is crucial for fetal development. The exact cause of this condition is unknown, but it involves inflammation of the intervillous space in the placenta. Over time, this inflammation can lead to poor placental function and adverse pregnancy outcomes. Early symptoms may include abnormal ultrasound findings, while late symptoms can result in fetal growth restriction or stillbirth. Early diagnosis is critical to manage and mitigate potential complications for both the mother and the fetus. The condition can cause significant stress and emotional impact on families due to its potential to affect pregnancy outcomes. Prognosis varies, but with careful monitoring and management, some pregnancies can reach term. Daily life for affected individuals involves frequent medical check-ups and monitoring to ensure the health of the pregnancy. Treatment options are limited, but emerging therapies targeting inflammation are being explored. Families may need psychological support to cope with the uncertainties and challenges posed by this condition. Overall, CIUE requires a multidisciplinary approach to care and management during pregnancy.
Chronic intervillositis of unknown etiology Symptoms
Symptoms vary in severity between individuals. Early diagnosis and management can significantly improve outcomes.
Very Common
Recurrent pregnancy loss manifests as the loss of two or more pregnancies before the fetus reaches viability. The biological mechanism involves chronic inflammation of the intervillous space, which disrupts placental function. Over time, this condition can lead to repeated pregnancy losses, causing significant emotional and physical stress. Management includes close monitoring and potential therapeutic interventions to improve pregnancy outcomes.
Placental insufficiency occurs when the placenta cannot deliver enough oxygen and nutrients to the fetus. This is caused by chronic inflammation and immune dysregulation within the placenta. As the condition progresses, it can lead to fetal growth restriction and other complications. Patients may require frequent ultrasounds and possible early delivery to manage the condition.
Fetal growth restriction is characterized by a fetus that is smaller than expected for the gestational age. The underlying cause is often inadequate blood flow and nutrient delivery due to placental inflammation. Over time, this can lead to increased risks of perinatal morbidity and mortality. Management strategies include enhanced prenatal care and monitoring to ensure timely intervention.
Common
Preterm birth is the delivery of a baby before 37 weeks of gestation. It is often a consequence of placental dysfunction and inflammation. As the condition progresses, it increases the risk of complications for both the mother and the baby. Management may involve medications to delay labor and interventions to support fetal lung development.
Maternal hypertension is high blood pressure during pregnancy, which can develop due to placental abnormalities. Chronic intervillositis can lead to increased vascular resistance and hypertension. If left unmanaged, it can progress to preeclampsia, posing risks to both mother and child. Regular blood pressure monitoring and medication can help manage this condition.
Abnormal placental pathology is identified through histological examination, showing inflammation and immune cell infiltration. This is caused by an immune-mediated response within the placenta. Over time, these changes can compromise placental function and fetal health. Pathological findings guide clinical management and future pregnancy planning.
Less Common
Neonatal complications can include respiratory distress and low birth weight, stemming from preterm birth and placental insufficiency. The inflammatory environment in the placenta affects fetal development. These complications can persist after birth, requiring specialized neonatal care. Early detection and intervention can mitigate long-term impacts.
Intrauterine fetal demise is the death of a fetus in the uterus after 20 weeks of gestation. It can result from severe placental dysfunction and inflammation. This condition can have profound psychological effects on the parents. Comprehensive prenatal care and monitoring are crucial to prevent such outcomes.
What Causes Chronic intervillositis of unknown etiology?
Chronic intervillositis of unknown etiology (CIUE) is not associated with a specific causative gene, as its etiology remains largely unknown. However, studies suggest that immune dysregulation plays a critical role in its pathogenesis. CD39, an ectonucleotidase encoded by the ENTPD1 gene located on chromosome 10q24, is downregulated in CIUE, which normally functions to hydrolyze ATP and ADP to AMP, modulating inflammation. Mutations or dysregulation in CD39 can lead to impaired ATP metabolism, resulting in excessive extracellular ATP accumulation. This accumulation triggers inflammasome activation and pro-inflammatory cytokine release, causing chronic inflammation. The inflammatory milieu disrupts placental function, leading to intervillous space infiltration by maternal immune cells. This immune response can damage placental villi, affecting nutrient and gas exchange. Neuroinflammation is not directly implicated in CIUE, but the immune response may have systemic effects. White matter degeneration is not a feature of CIUE, but placental dysfunction can lead to fetal growth restriction. Symptoms of CIUE, such as recurrent pregnancy loss, appear due to placental insufficiency. The variability in disease severity among patients may be influenced by genetic predispositions, environmental factors, and the extent of immune dysregulation. Further research is needed to elucidate the genetic and molecular underpinnings of CIUE.
How is Chronic intervillositis of unknown etiology Diagnosed?
Typical age of diagnosis: Chronic intervillositis of unknown etiology is typically diagnosed during the reproductive years, often after recurrent pregnancy losses or adverse perinatal outcomes. Diagnosis usually occurs after a detailed evaluation of placental pathology following a miscarriage or stillbirth. Women may present with a history of recurrent miscarriages, intrauterine growth restriction, or preterm birth. The condition is often identified in women undergoing evaluation for unexplained reproductive challenges.
Clinicians look for a history of recurrent pregnancy loss, intrauterine growth restriction, or preterm delivery. Important history elements include previous obstetric outcomes and any known autoimmune conditions. Physical examination may reveal signs of pregnancy complications such as hypertension or fetal growth restriction. This step helps to identify patients who may benefit from further diagnostic testing for chronic intervillositis.
Ultrasound is the primary imaging modality used to assess fetal growth and placental structure. Abnormalities such as placental thickening or reduced blood flow may be visible. These findings can support the diagnosis of chronic intervillositis when correlated with clinical history. Imaging helps exclude other conditions like placental abruption or molar pregnancy.
Specific tests include placental histopathology to identify inflammatory infiltrates. Biomarkers such as elevated inflammatory cytokines or abnormal placental proteins are sought. Abnormal results show increased intervillous inflammatory cells and fibrin deposition. These results guide further management and potential therapeutic interventions.
Genetic testing may involve sequencing genes related to immune regulation. Mutations or polymorphisms in genes affecting immune response may be found. Results can confirm a predisposition to immune-mediated placental disorders. Genetic findings inform family counseling regarding recurrence risks and potential interventions.
Chronic intervillositis of unknown etiology Treatment Options
Immunosuppressive drugs such as corticosteroids are used to modulate the immune response. These drugs work by reducing inflammation and immune cell activity in the placenta. Specific drugs used include prednisone and azathioprine. Clinical evidence suggests these drugs can improve pregnancy outcomes in some cases. Limitations include potential side effects like increased infection risk and the need for careful monitoring.
Techniques include biofeedback and muscle strengthening exercises. The therapeutic goal is to improve pelvic support and reduce stress on the uterus. Sessions are typically conducted weekly for several months. Measurable outcomes include improved pelvic muscle tone and reduced pregnancy-related discomfort. Long-term benefits may include reduced risk of preterm labor.
Indicated for diagnostic confirmation when non-invasive methods are inconclusive. The procedure involves obtaining a small sample of placental tissue for histological examination. Expected benefits include definitive diagnosis and targeted treatment planning. Surgical risks include bleeding and infection. Post-operative care requires monitoring for complications and follow-up consultations.
The team includes obstetricians, immunologists, and mental health professionals. Specific interventions focus on monitoring pregnancy progression and managing complications. Psychosocial support strategies address anxiety and stress related to pregnancy outcomes. Family education covers condition management and lifestyle modifications. Long-term monitoring includes regular follow-ups and adjustment of care plans as needed.
When to See a Doctor for Chronic intervillositis of unknown etiology
- Severe abdominal pain — this could indicate a serious complication such as placental abruption requiring immediate medical attention.
- Heavy vaginal bleeding — this is an emergency as it may signify a miscarriage or other serious placental issue.
- Sudden decrease in fetal movements — this could indicate fetal distress or demise, necessitating urgent evaluation.
- Persistent mild abdominal discomfort — this may suggest ongoing inflammation and should be evaluated by a healthcare provider.
- Unexplained fever during pregnancy — could indicate an infection or inflammatory process requiring medical assessment.
- Unusual fatigue or weakness — may be a sign of anemia or other underlying issues related to the condition.
- Mild intermittent abdominal cramps — monitor for changes in intensity or frequency and consult a doctor if they worsen.
- Occasional light spotting — monitor for any increase in volume or frequency and seek advice if concerned.
Chronic intervillositis of unknown etiology — Frequently Asked Questions
Is this condition hereditary?
Chronic intervillositis of unknown etiology is not typically considered hereditary. The probability of passing it to children is currently unknown due to its unclear etiology. De novo mutations have not been implicated in this condition. Carrier status is not applicable as it is not linked to a specific genetic mutation. Genetic counseling may be recommended to discuss potential risks and family planning.
What is the life expectancy for someone with this condition?
The prognosis largely depends on the severity and management of the condition during pregnancy. Factors such as early intervention and appropriate treatment can improve outcomes. Mortality is primarily related to adverse pregnancy outcomes rather than direct effects on the mother. Effective management can significantly enhance survival rates of the fetus. Realistic expectations should include close monitoring and potential interventions to optimize pregnancy outcomes.
How is this condition diagnosed and how long does diagnosis take?
Diagnosis typically involves histopathological examination of the placenta after delivery. The time from first symptoms to diagnosis can vary, often occurring postpartum. Specialists such as obstetricians and pathologists are usually involved in the diagnostic process. Delays may occur due to the rarity and nonspecific symptoms of the condition. Confirmation is achieved through placental biopsy showing characteristic inflammation.
Are there any new treatments or clinical trials available?
Recent research is exploring inflammasome-targeted therapies as a promising approach. Gene therapy is not currently applicable, but novel anti-inflammatory treatments are under investigation. Clinical trials can be found on ClinicalTrials.gov by searching for chronic intervillositis. Patients should discuss potential trial participation with their healthcare provider. New treatments may become available in the coming years as research progresses.
How does this condition affect daily life and activities?
The condition primarily affects pregnancy and may not directly impact daily life outside of this context. Educational implications are minimal unless complications arise during pregnancy. Social and emotional challenges may include anxiety related to pregnancy outcomes. Family burden can be significant due to the need for frequent medical appointments and monitoring. Support from healthcare providers and community resources can help manage these challenges.
Support & Resources
References
Content generated with support from peer-reviewed literature via PubMed.
- 1.Reproductive and treatment outcomes in chronic intervillositis of unknown etiology: A systematic review and meta-analysis.
Simula N, McRae K, Habte R et al. · J Reprod Immunol · 2024 · PMID: 38941926
- 2.Towards standardized criteria for diagnosing chronic intervillositis of unknown etiology: A systematic review.
Bos M, Nikkels PGJ, Cohen D et al. · Placenta · 2018 · PMID: 29277275
- 3.CD39 downregulation in chronic intervillositis of unknown etiology.
Sato Y, Maekawa K, Aman M et al. · Virchows Arch · 2019 · PMID: 31218404
- 4.Clinical outcomes in chronic intervillositis of unknown etiology.
Bos M, Harris-Mostert ETMS, van der Meeren LE et al. · Placenta · 2020 · PMID: 32174302
- 5.Inflammasome-targeted therapy might prevent adverse perinatal outcomes of recurrent chronic intervillositis of unknown etiology.
Mattuizzi A, Sauvestre F, Fargeix T et al. · Nat Commun · 2024 · PMID: 39477918
- 6.Chronic Intervillositis of Unknown Etiology (CIUE): Prevalence, patterns and reproductive outcomes at a tertiary referral institution.
Simula NK, Terry J, Kent NE et al. · Placenta · 2020 · PMID: 32841927
- 7.Reproducibility of Grading in Chronic Intervillositis of Unknown Etiology.
Ongaro D, Terry J · Pediatr Dev Pathol · 2020 · PMID: 31615340
- 8.Placental interferon signaling is involved in chronic intervillositis of unknown etiology.
Terry J, Bedaiwy MA · Placenta · 2022 · PMID: 35580406
This content is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.Last reviewed: 2026-05-04